• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » M2S Acquires DXA Resource Group

M2S Acquires DXA Resource Group

January 26, 2009
CenterWatch Staff

M2S’ recent acquisition of DXA Resource Group (DRG) will enable the imaging company to offer new and specialized capabilities and expertise to sponsors of clinical trials.

The West Lebanon, N.H., company has provided image and data management services for clinical trials since 1992, but the company did not provide Dual X-ray Absorptiometry (DXA) services. DXA, an imaging modality used to measure bone mineral density and body mass composition, is increasingly used in clinical trials.

“From a strategic point of view, we’re very interested in the DXA business. It’s a business that has been a substantial part of the total scan volume of imaging clinical trials for a long period of time,” said M2S president and CEO Wes Chapman.

M2S clients had requested DXA services, but, until the acquisition of DRG, the company did not have the capabilities to support DXA’s complexities.

“DXA is a very particular niche. It has its own image analytical tools, and there’s a fairly highly specialized scientific platform behind it. If you want to be in the DXA business, you really need to be in there with a group of people that have the experience with the imaging technology, with the imaging analytical techniques, and with the science that underlies the imaging technique,” Chapman said.

With the acquisition of DRG and its proprietary system, M2S can now provide quality assurance and management of clinical trials involving DXA measurements. DRG was one of only a handful of companies that offered DXA quality assurance and related customer service, Chapman said.

“We were among probably three major [DXA] providers,” said Reta Rupich, DRG’s co-founder and former president.

Rupich, now the newly appointed vice president of M2S’ DXA division, co-founded DRG in 2002. Although the company provided a unique and necessary service to pharmaceutical and medical device companies, DRG’s small size restricted its growth. “We were at a disadvantage before this acquisition because of our size and resources. I think this joining of forces really puts us up there on the top in terms of being able to offer state of the art, cutting edge DXA services,” Rupich said.

DRG’s six-person team remains intact with this acquisition, and Rupich’s two co-founders will also stay on with M2S.

The DXA division is located in Westborough, Mass., in DRG’s former office. Although the two companies are a state away from each other, M2S’ trial management technologies will make the long-distance working arrangement seamless, Rupich said.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing